Abbott

ABT

Market cap $224B

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW, and ALB, have posted double-digit gains in 2025, while others lag behind. Dividend growth among Aristocrats averages 5.46% for 2025, with most constituents announcing increases, though growth is slightly below 2024 levels.

Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact Sciences Corporation (NasdaqCM: EXAS) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of Exact Sciences will receive $105.00 in cash for each share of Exact Sciences that they own. KSF is seeking to determine whether this consideration and the proc.

These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.

Abbott and Medtronic are innovative healthcare leaders that generate consistent revenue and profits. They also have attractive long-term prospects and have consistently raised their dividend payouts.

Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high-teens organic growth.

Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ: EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

Abbott Laboratories agrees to buy the cancer screening company in a cash deal.

Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.